Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.64 |
| ▸ | SELL | P14151 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
| ▸ | FUT4 | P22083 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095257 | 0.84 | TTR (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2961991 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30413369 | 0.84 | TTR (0.59) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL30375631 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL678990 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL8088102 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL29484566 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1845406 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL15012 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL4918056 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112973448-B | Composite reverse osmosis membrane with chlorine resistance body, preparation method and application thereof | 南京理工大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-112973449-B | Polyester composite reverse osmosis membrane with chlorine resistance as body and preparation method and application thereof | 南京理工大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-112973449-A | Polyester composite reverse osmosis membrane with chlorine resistance and preparation method and application thereof | 南京理工大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-112973448-A | Composite reverse osmosis membrane with chlorine resistance body, preparation method and application thereof | 南京理工大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-105612158-B | The somatostatin receptor hypotype 5 (SSTR5) antagonist | 武田药品工业株式会社 | 2017-06-30 | — | — | CN | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-101426753-A | Hydroxylated long-chain resveratrol derivatives as neurotrophic agents | CENTRE NAT RECH SCIENT (FR) | 2009-05-06 | — | — | CN | disclosed |
| WO-2007099162-A2 | HYDROXYLATED LONG-CHAIN RESVERATROL DERIVATIVES USEFUL AS NEUROTROPHIC AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-09-07 | — | — | WO | disclosed |
| CN-1186328-C | Substd. 5-benzyl-2,4-diaminopyrimidines | BASLIDE PHARMA AG (CH) | 2005-01-26 | — | — | CN | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| CN-1387516-A | Substd. 5-benzyl-2,4-diaminopyrimidines | BASLIDE PHARMA AG (CH) | 2002-12-25 | — | — | CN | disclosed |
| EP-1230224-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032633-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | BDNF, NTRK2, NGF | CA12 2802/4885CA1 1189/4885CA2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.